This activity is part 2 in a 4-part webinar series.
Program Description
Patients with breast cancer are classified into subtypes based on hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, and tumor staging. HER2 is overexpressed in 15% to 20% of breast cancer cases while tumor-associated calcium signal transducer 2 (Trop-2) is overexpressed in all breast cancer subtypes. Oncology pharmacists must be familiar with emerging treatments that target antigens present in breast cancer cells, including antibody-drug conjugates (ADCs) that are FDA approved or currently under investigation for breast cancer. This webinar will explore clinical data for the use of ADCs in the treatment of breast cancer subtypes, including HER2-low expression and triple-negative breast cancer. Additionally, differences between HER2-targeted and Trop-2-targeted ADCs in the treatment of metastatic breast cancer will also be reviewed.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 18, 2023
Expiration date: July 18, 2023
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the role and prevalence of target antigens in various breast cancer subtypes
- Analyze safety and efficacy data for human epidermal growth factor receptor 2- and tumor-associated calcium signal transducer 2-targeted antibody-drug conjugates in the treatment of patients with breast cancer
- Explore emerging clinical evidence for novel antibody-drug conjugates or indications in the treatment of metastatic breast cancer
Julia L. Ziegengeist, PharmD, BCOP
Clinical Pharmacist Coordinator, Solid Tumor Oncology
Atrium Health Levine Cancer Institute
Charlotte, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-134-L01-P. The activity is available for CE credit through July 18, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Julia L. Ziegengeist, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Amy L. Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms